COPENHAGEN, Denmark, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on its Vision 3x3 strategic roadmap and planned 2023 key corporate milestones.

Company sets ambitious vision for €480 million in recurring revenues and a 40% EBITDA margin by 2030; outlines roadmap for accelerated AI-driven growth and innovation. Dublin, Ireland--(Newsfile Corp.

The new year marks the commencement of insightful dialogues surrounding emerging trends, innovative technologies, progressive business strategies and engaging interviews with esteemed industry leaders ...

Expects High-Single-Digit Annual Net Revenue Growth and Annual Adjusted Operating Margin 1 Expansion of 50 to 150 Basis Points Through Fiscal 2030 Provides Planning Scenario of High-Single-Digit Net ...

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Carlisle Companies Incorporated (NYSE:CSL), a leading supplier of innovative building products and solutions, today released a video and presentation featuring its ...

MT. LAUREL, N.J.--(BUSINESS WIRE)--InTest Corporation (NYSE American: INTT), a global supplier of innovative test and process technology solutions for use in manufacturing and testing in key target ...

In many businesses, the quest for immediate revenue often overshadows the need for long-term vision and sustainability. Managing this delicate equilibrium between short-term gains and future-oriented ...

The vision, strategic priorities and theory of change are established at the beginning of the PLAN for Results phase, based on a well-developed situation analysis and planning scenario. This helps ...

Capability development will remain a key priority for the Indian armed forces, involving the upgrading and sustenance of existing platforms, induction of cutting-edge weapon systems and the adoption ...